1302P MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
Cho, B.C., Ahn, M-J., Kim, T.M., Kim, S-W., Han, J-Y., Kim, C., Shim, B., Ricordel, C., Drilon, A.E., Pujol, J-L., Gray, J.E., Villaruz, L., Blumenschein, G., Perez, J., Modi, D.A., Kaul, M., Patel, S., Hao, Y., Kim, E., Magnan, H.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
PF254 RESULTS FROM THE FIRST‐IN‐HUMAN STUDY OF MIVEBRESIB (ABBV‐075), A PAN‐INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Borthakur, G., Odenike, O., Wolff, J.E., Aldoss, I., Rizzieri, D., Prebet, T., Hu, B., Dinh, M.H., Chen, X., Modi, D.A., Freise, K.J., Jonas, B.A.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article